Thorsten Kühn

Neoadjuvant Treatment With Trastuzumab in HER2-Positive Breast Cancer: Results From the GeparQuattro Study

Michael Untch, Mahdi Rezai, Sibylle Loibl et al. · Journal of Clinical Oncology · 2010 · 550 citations · Full text

Surgical Oncology, Oncology, High Pcr Rate +13

Pathologic Complete Response After Neoadjuvant Chemotherapy Plus Trastuzumab Predicts Favorable Survival in Human Epidermal Growth Factor Receptor 2–Overexpressing Breast Cancer: Results From the TECHNO Trial of the AGO and GBG Study Groups

Michael Untch, Peter A. Fasching, Gottfried E. Konecny et al. · Journal of Clinical Oncology · 2011 · 508 citations

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial

Michael Untch, Sibylle Loibl, Joachim Bischoff et al. · The Lancet Oncology · 2012 · 453 citations

Gbg 44, Medicine, Randomised Phase 3 +7

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 404 citations · Full text

Breast Oncology, Overall Survival, Medicine +7

FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters

Andreas K. Buck, Holger Schirrmeister, Thorsten Kühn et al. · European Journal of Nuclear Medicine and Molecular Imaging · 2002 · 303 citations

Fdg Uptake, Breast Oncology, Medicine +8